TherapeuticsMD (TXMD) Misses Q3 EPS by $1.09

TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($3.13), $1.09 worse than the analyst estimate of ($2.04). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $30.2 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Circle Internet stock climbs on TD Cowen upgrade, Fed rate hike
• UBS cuts KOSPI target by nearly 10% to reflect higher rates